Related Experiment Video

Updated: Jun 1, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Targeting mTOR signaling pathway in ovarian cancer

S Mabuchi1, T Hisamatsu, T Kimura

  • 1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. smabuchi@gyne.med.osaka-u.ac.jp

Current Medicinal Chemistry
|June 10, 2011
PubMed

Insights

Mammalian target of rapamycin (mTOR) inhibitors show promise for treating epithelial ovarian cancer. Novel ATP-competitive inhibitors are being developed to overcome resistance and enhance therapeutic benefits in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) pathway is frequently hyperactivated in epithelial ovarian cancer.
  • mTOR signaling plays a critical role in tumor cell proliferation and survival.
  • mTOR is recognized as a significant therapeutic target for ovarian cancer treatment.

Purpose of the Study:

  • To review the scientific rationale for targeting the mTOR pathway in epithelial ovarian cancer.
  • To summarize preclinical evidence supporting mTOR inhibitor efficacy.
  • To discuss the potential clinical benefits of novel mTOR inhibitors.

Main Methods:

  • Review of preclinical studies on rapamycin and its analogs in ovarian cancer models.
  • Analysis of data from ongoing Phase I/II clinical trials of mTOR inhibitors.
  • Examination of the mechanisms of action for novel ATP-competitive mTOR inhibitors.

Main Results:

  • Preclinical studies demonstrate significant growth inhibition of ovarian cancer by mTOR inhibitors, both as monotherapy and in combination with chemotherapy.
  • Ongoing clinical trials are evaluating the safety and efficacy of mTOR inhibitors in ovarian cancer patients.
  • Development of novel ATP-competitive mTOR inhibitors aims to address resistance mechanisms observed with earlier agents.

Conclusions:

  • mTOR inhibitors represent a promising therapeutic strategy for epithelial ovarian cancer.
  • Novel mTOR inhibitors offer potential for overcoming treatment resistance.
  • Further clinical evaluation is warranted to establish the role of mTOR inhibitors in ovarian cancer management.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...